Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas

Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme. For some of these tumors relapse and mortality rates are still significantly high. Therefore, further studies are needed to better understand pathogenetic processes underlying sarcomas to offer new and more effective treatments. Next generation sequencing (NGS) has opened new frontiers for cancer research allowing to identify somatic or constitutional mutations known or yet unknown with the aim to better understand carcinogenesis. The establishment of the genomic profile of the tumor could also help clinicians to personalize patients treatment based on their genetic and molecular alterations.

NCT Number	NCT04621201
Lead Sponsor	Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna Collaborators: Associazione Italiana Ematologia Oncologia Pediatrica
Conditions	Diagnosed or Relapsed/Refractory Sarcomas
Enrollment	120 participants
Start Date	2018-12-06
Primary Completion	2024-12-06 (estimated)
Study Completion	2026-12-06 (estimated)
Updated on ClinicalTrials.gov	2023-03-29